Last reviewed 2026-04-20 · How we verify

Cyclolyt (CYCLANDELATE)

Phase 2 active Small molecule Quality 22/100

Cyclolyt (generic name: CYCLANDELATE) is a cyclandelate drug. It is currently in Phase 2 development.

Cyclolyt works by affecting blood vessel function and improving circulation.

Cyclolyt (CYCLANDELATE) is a small molecule drug in the cyclandelate class. Its exact target is unknown, but it is used to treat certain conditions. The commercial status of Cyclolyt is unclear, and it may be patented or have generic manufacturers. Key safety considerations are not well-documented. Further research is needed to fully understand its pharmacology and clinical use.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CYCLANDELATE
Drug class	cyclandelate
Modality	Small molecule
Therapeutic area	Hematology
Phase	Phase 2

Mechanism of action

Imagine your blood vessels are like roads in your body. Cyclolyt helps to improve the flow of traffic on these roads, making it easier for oxygen and nutrients to reach your cells. This can be especially helpful for people with conditions that affect blood flow.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cyclolyt CI brief — competitive landscape report
Cyclolyt updates RSS · CI watch RSS

Frequently asked questions about Cyclolyt

What is Cyclolyt?

Cyclolyt (CYCLANDELATE) is a cyclandelate drug.

How does Cyclolyt work?

Cyclolyt works by affecting blood vessel function and improving circulation.

What is the generic name of Cyclolyt?

CYCLANDELATE is the generic (nonproprietary) name of Cyclolyt.

What drug class is Cyclolyt in?

Cyclolyt belongs to the cyclandelate class. See all cyclandelate drugs at /class/cyclandelate.

What development phase is Cyclolyt in?

Cyclolyt is in Phase 2.

Drug class: All cyclandelate drugs
Therapeutic area: All drugs in Hematology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing